<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00533091</url>
  </required_header>
  <id_info>
    <org_study_id>MI-CP151</org_study_id>
    <nct_id>NCT00533091</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Safety of Multi-Dose MEDI-545 in Adult Patients With Dermatomyositis or Polymyositis</brief_title>
  <official_title>A Phase 1B, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate Safety of Multiple-Dose, Intravenously Administered MEDI-545, A Fully Human Anti Interferon-Alpha Monoclonal Antibody, In Adult Patients With Dermatomyositis or Polymyositis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate the safety and tolerability of multiple IV
      doses of MEDI-545 in adult patients with myositis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the study is to evaluate the safety and tolerability of multiple
      intravenous (IV) doses of MEDI-545 in adult patients with dermatomyositis (DM) or
      polymyositis (PM).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoints of the study are safety and tolerability of multiple intravenous (IV) doses of MEDI-545 in adult patients with Dermatomyositis or Polymyositis, assessed primarily by summarizing AEs assessing changes in viral cultures and titers.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary endpoints of the study are the PK and IM of multiple IV doses of MEDI-545.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The third endpoint of the study are the evaluations of disease activities.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>DERMATOMYOSITIS OR POLYMYOSITIS</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MEDI-545</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI-545</intervention_name>
    <description>MEDI-545 is supplied as a sterile liquid containing 0.75 mL of MEDI-545 solution at a concentration of 100 mg/mL in a 3 mL single-use glass vial.
Dosage, frequency and duration: MEDI-545 (0.3, 1.0, 3.0, or 10.0 mg/kg) will be administered via infusion over at least 60 minutes every 2 weeks for 26 weeks.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dosage form: Placebo is supplied as a sterile liquid containing a 0.75 mL solution in a 3 mL single-use vial.
Dosage, frequency and duration: Placebo (0.3, 1.0, 3.0, or 10.0 mg/kg) will be administered via infusion over at least 60 minutes every 2 weeks for 12 weeks.
Thereafter, subjects will receive MEDI-545, at the dose specified in the dose cohort they are assigned, every 2 weeks for an additional 12 weeks.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female adults at least 18 years of age at the time of randomization;

          -  Written informed consent obtained from the patient or the patient's legal
             representative prior to receipt of any study medication or beginning study procedures;

          -  Probable or definite PM or DM according to the Bohan and Peter criteria (Bohan, 1975);

          -  For patients with PM, documentation of a muscle biopsy result that is consistent with
             the diagnosis of PM;

          -  All patients including those with DM must meet at least two of the following criteria:

          -  Strength in MMT greater ≥ 80/150 but ≤ 125/150 using the MMT-8 muscle group testing;

          -  Patient Global Activity Assessment by visual analog scale (VAS)≥ 2.0 cm on a 10 cm
             scale, which is included as part of CLINHAQ;

          -  Physician Global Activity Assessment by VAS ≥ 2.0 cm on a 10 cm scale, which is
             included as part of MDAAT;

          -  CLINHAQ disability index ≥ 0.25;

          -  Global extramuscular activity assessment ≥ 1.0 cm on a 10-cm VAS scale (this measure
             is the physician's composite evaluation and is based on assessments of activity scores
             on the constitutional, cutaneous, skeletal, gastrointestinal, pulmonary and
             cardiovascular scales of the MDAAT;

          -  Subjects with PM must have an elevation of serum CK or aldolase at a minimum level of
             1.3 x upper limit of normal (ULN) or serum CK or aldolase at least 2-fold higher than
             the patient's own lowest value since diagnosis;

          -  Subjects with DM must have either an elevated CK or aldolase as above (per inclusion
             criterion #6) or other laboratory evidence of active myositis. This could include
             either abnormal signal on skeletal muscle MRI suggestive of inflammation or an
             electromyogram demonstrated muscle membrane irritability (e.g., fibrillation
             potentials, positive sharp waves, complex repetitive discharges) and short duration,
             small amplitude, polyphasic motor unit action potentials;

          -  For patients randomized to Dose Cohorts 1.2, 3A and 4: median fold overexpression of
             the top 25 type I IFN inducible genes of four-fold or greater in whole blood at the
             time of screening; For patients randomized to dose cohort 3B: low or negative
             expression of type I IFN-inducible genes;

          -  Sexually active women, unless surgically sterile (including tubal ligation) or at
             least 2 years postmenopausal, must use an effective method of avoiding pregnancy
             (including oral, injectable, transdermal, or implanted contraceptives, intrauterine
             device, diaphragm with spermicide, cervical cap, abstinence, and sterile sexual
             partner) in addition to the use of condoms (male or female condoms with spermicide)
             from screening through end of study. Cessation of birth control after this point
             should be discussed with a responsible physician. Sexually active males, unless
             surgically sterile, must likewise practice two effective methods of birth control
             (condom with spermicide or abstinence) and must use such precautions from Study Day 0
             through end of study;

          -  Ability to complete the study period, including follow-up period, of up to 350 days;
             and

          -  Willing to forego other forms of experimental treatment during the study.

        Exclusion Criteria:

          -  Receipt of MEDI-545 in any previous clinical study or prior randomization into the
             trial;

          -  History of allergy or reaction to any component of the study drug formulation;

          -  Inclusion body myositis, cancer-associated myositis, myositis associated with another
             connective tissue disease, environmentally-associated myositis, or drug-related
             myopathy;

          -  A history of or a family history of noninflammatory myopathy, scapular winging,
             atrophy, or hypertrophy of the calf muscles;

          -  Receiving prednisone &gt; 35 mg/day (or an equivalent dose of another corticosteroid)
             within 14 days before Study Day 0;

          -  Receiving the following dosages of medications within 28 days before Study Day 0:
             hydroxychloroquine &gt; 600 mg/day, mycophenolate mofetil &gt; 3 g/day, methotrexate &gt; 25
             mg/week, azathioprine &gt; 3 mg/kg/day, or any dose of cyclophosphamide, cyclosporine, or
             thalidomide;

          -  Have received fluctuating doses of antimalarials, mycophenolate mofetil, methotrexate,
             leflunomide, or azathioprine within 28 days before Study Day 0 or fluctuating doses of
             corticosteroids within 14 days before Study Day 0;

          -  Have received leflunomide &gt; 20 mg/day in the 6 months prior to Study Day 0;

          -  Treatment with any investigational drug therapy within 28 days before Study Day 0 or
             biologic therapies (eg, rituximab) within 30 days or 5 half-lives of the biologic
             agent, whichever is longer, before Study Day 0;

          -  In the investigator's opinion, evidence of clinically significant active infection,
             including ongoing, chronic infection, within 28 days before Study Day 0;

          -  A history of severe viral infection as judged by the investigators, including severe
             infections of either CMV or the herpes family such as disseminated herpes, herpes
             encephalitis, ophthalmic herpes;

          -  Herpes zoster ≤ 3 months prior to Study Day 0;

          -  Evidence of infection with hepatitis B or C virus or HIV-1 or HIV-2, or active
             infection with hepatitis A, as determined by results of testing at screening;

          -  Vaccination with live attenuated viruses within 28 days before Study Day 0;

          -  Pregnancy (sexually active women, unless surgically sterile or at least 2 years
             post-menopausal, must have a negative serum pregnancy test at screening and a negative
             urine pregnancy test prior to study drug administration on Study Day 0);

          -  Breastfeeding or lactating women;

          -  History of alcohol or drug abuse &lt; 1 year prior to Study Day 0;

          -  History of cancer, except for basal cell carcinoma or carcinoma in situ of the cervix
             treated with apparent success with curative therapy more than 1 year prior to Study
             Day 0;

          -  History of active tuberculous infection;

          -  History of latent tuberculous infection or newly positive TB skin test (reaction
             defined as ≥ 10 mm in diameter if not on systemic immunosuppressive medication or ≥ 5
             mm if on systemic immunosuppressive medication) without completion of an appropriate
             course of treatment or ongoing prophylactic therapy;

          -  A history of coagulation disorders that in the opinion of the investigator would
             contraindicate skin or muscle biopsies;

          -  Elective surgery planned from the time of screening through Study Day 196;

          -  At screening blood tests (must be within 28days before Study Day 0) any of the
             following:

               -  Serum creatinine &gt; 4.0 mg/dL,

               -  Neutrophils &lt; 1,500/mm3,

               -  Platelet count &lt; 50,000/mm3;

          -  History of any disease, evidence of any current disease (other than DM or PM), any
             finding upon physical examination, or any laboratory abnormality, that, in the opinion
             of the investigator or medical monitor, may compromise the safety of the patient in
             the study or confound the analysis of the study; or

          -  Any employee of the research site who is involved with the conduct of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominique Ethgen, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cumberland</city>
        <state>Maryland</state>
        <zip>21502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2007</study_first_submitted>
  <study_first_submitted_qc>September 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2007</study_first_posted>
  <last_update_submitted>May 25, 2012</last_update_submitted>
  <last_update_submitted_qc>May 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatomyositis</mesh_term>
    <mesh_term>Polymyositis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

